47 phenotypes from 1 allele in 1 genetic background

Allelic Composition Genetic Background	Annotated Term	Reference
Slc33a1tm1.1Lpu/Slc33a1+ involves: 129S7/SvEvBrd * C57BL/6	abnormal autophagy	J:211266
	abnormal circulating cytokine level	J:211266
	abnormal corpus callosum morphology	J:211266
	abnormal cytokine secretion	J:211266
	abnormal enzyme/coenzyme activity	J:211266
	abnormal motor capabilities/coordination/movement	J:211266
	abnormal spinal cord white matter morphology	J:211266
	abnormal T cell activation	J:211266
	astrocytosis	J:211266
	axon degeneration	J:211266
	brain inflammation	J:211266
	conjunctivitis	J:211266
	decreased B cell number	J:211266
	decreased corpus callosum size	J:211266
	decreased grip strength	J:211266
	decreased survivor rate	J:211266
	demyelination	J:211266
	dermatitis	J:211266
	gliosis	J:211266
	normal immune system phenotype	J:211266
	increased B cell number	J:211266
	increased circulating interleukin-17 level	J:211266
	increased circulating interleukin-18 level	J:211266
	increased inflammatory response	J:211266
	increased interferon-gamma secretion	J:211266
	increased interleukin-4 secretion	J:211266
	increased interleukin-17 secretion	J:211266
	increased lung adenoma incidence	J:211266
	increased lymphoma incidence	J:211266
	increased neutrophil cell number	J:211266
	increased sarcoma incidence	J:211266
	increased susceptibility to infection	J:211266
	increased thermal nociceptive threshold	J:211266
	increased tumor incidence	J:211266
	limb grasping	J:211266
	microgliosis	J:211266
	normal neoplasm	J:211266
	neurodegeneration	J:211266
	neuron degeneration	J:211266
	preputial gland inflammation	J:211266
	prostate gland inflammation	J:211266
	salivary gland inflammation	J:211266
	spinal cord degeneration	J:211266
	stomach inflammation	J:211266
	urinary bladder inflammation	J:211266
Slc33a1tm1.1Lpu/Slc33a1tm1.1Lpu involves: 129S7/SvEvBrd * C57BL/6	embryonic growth arrest	J:211266
	embryonic growth retardation	J:211266